Sarah Walsh
Manager, Data Analytics & Evidence Synthesis
Expertise:
Sarah is a Manager on the Value & Evidence team at EVERSANA and provides statistical support and guidance on evidence synthesis projects.
Sarah brings over six years of academic experience and a strong background in research and data analysis. Since joining EVERSANA in November 2020, she has contributed to evidence synthesis projects in various disease areas such as oncology, rheumatology, and hematology. Her expertise focuses on the development and execution of ITC analyses including matching-adjusted indirect comparisons, network meta-analyses, meta-analyses, and inverse probability of treatment weighting. Sarah also has experience with targeted literature reviews and medical writing.
Prior to joining EVERSANA, she graduated from the University of Waterloo with a Master of Applied Mathematics (MMath). She has also completed a Bachelor of Science (BSc) from Cape Breton University with a major in mathematics and a minor in psychology.
Articles by Sarah Walsh
Evaluating Talazoparib Plus Enzalutamide Against Standard of Care Therapies in Metastatic Castration-Resistant Prostate Cancer: A Matching-Adjusted Indirect Comparison
Metastatic castration-resistant prostate cancer (mCRPC) is an incurable condition associated with poor prognosis and reduced quality of life. Historically, treatment options were limited, and despite recent advancements, the five-year survival rate for metastatic prostate cancer remains low at approximately 34%. The current standard of care for newly diagnosed mCRPC patients includes androgen receptor pathway inhibitors such as abiraterone acetate, as well as docetaxel chemotherapy. However, the treatment landscape is evolving with the introduction of new therapies. Among these, poly (ADP-Ribose) polymerase (PARP) inhibitors, in combination with androgen receptor pathway inhibitors like talazoparib plus enzalutamide, have shown promising results in clinical trials. However, talazoparib plus enzalutamide, abiraterone acetate and docetaxel have […]
Evaluating PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Matching-Adjusted Indirect Comparison
Metastatic castration-resistant prostate cancer (mCRPC) is an incurable condition associated with poor prognosis and quality of life. Historically, patients with mCRPC had limited therapeutic options, and despite advancements in therapeutic innovation, the five-year relative survival rate for metastatic prostate cancer remains low (~34%). Encouragingly, multiple randomized clinical trials have recently demonstrated promising responses to novel poly (ADP-ribose) polymerase (PARP) inhibitors – such as talazoparib, niraparib and olaparib, in combination with androgen receptor pathway inhibitors – and represent a new class of therapies for first-line treatment of mCRPC. However, there has been no direct comparative trial conducted between these combinations of PARP and androgen receptor pathway inhibitors. When such trial data […]
The Importance of Quality-of-Life Metrics in mCRPC
Prostate cancer is one of the most diagnosed malignancies in the world, with many patients progressing to an advanced stage of the disease called metastatic castration-resistant prostate cancer (mCRPC). Due to the poor prognosis and incurable nature of mCRPC, maintaining or improving quality of life (QoL) has become an important goal of therapy for patients, caregivers and physicians QoL metrics are also essential in the approval and reimbursement of cancer therapies. Quality of life can be measured using utility values, such as the EQ-5D family of instruments. The EQ-5D scales measure QoL through five dimensions of health – mobility, self-care, usual activities, pain and discomfort, and anxiety and depression – […]